Shares of Sarepta Therapeutics SRPT plunged greater than 20% yesterday after the corporate reported the dying of a affected person after therapy with Elevidys, its one-shot gene remedy for Duchenne muscular dystrophy (DMD).
Per the corporate, this affected person died of acute liver failure. Whereas acute liver harm is a identified danger of Elevidys, that is the primary time a dying has been reported of anybody taking the remedy. Nevertheless, Sarepta acknowledged that the affected person additionally had a latest CMV an infection, which can have contributed to the end result, as CMV can injury the liver.
Sarepta has reported the occasion to well being authorities, medical examine investigators and prescribing physicians. It intends to replace Elevidys’ prescribing data accordingly. Regardless of the incident, the corporate maintains that the benefit-risk profile of its gene remedy stays constructive, with over 800 sufferers handled in medical research or industrial use.
SRPT Inventory Efficiency
The plunge in Sarepta’s inventory was doubtless as a consequence of considerations that the occasion might make medical doctors extra hesitant to prescribe Elevidys and even gradual general market adoption. Elevidys accounted for almost 60% of the corporate’s whole revenues within the fourth quarter of 2024. The corporate anticipates internet product revenues within the vary of $2.9-$3.1 billion for this full 12 months, two-thirds of that are anticipated to return from the gene remedy’s gross sales. Any setback to Elevidys’ uptake could possibly be detrimental to SRPT’s progress trajectory and inventory efficiency.
12 months so far, Sarepta’s shares have plunged almost 40% towards the industry’s 6% progress.
Picture Supply: Zacks Funding Analysis
Sarepta’s Sturdy Industrial DMD Portfolio
Sarepta’s portfolio consists of 4 accredited therapies, all focusing on DMD indications.
At present, Elevidys is the primary and solely one-shot gene remedy for DMD in the US. Since its industrial launch in June 2023, the gene remedy has demonstrated blockbuster potential. Sarepta added about $821 million from Elevidys gross sales in 2024 in contrast with $200 million within the year-ago interval.
Elevidys has been developed by Sarepta in partnership with pharma big Roche RHHBY. SRPT and RHHBY entered right into a licensing settlement in 2019 to develop Elevidys. Per the settlement, Roche has unique rights to launch and market the remedy in ex-U.S. markets.
Aside from Elevidys, Sarepta has three different therapies in its industrial portfolio focusing on the DMD affected person inhabitants. Exondys 51 is the primary accredited disease-modifying remedy for DMD in the US in addition to the corporate’s first product to obtain advertising and marketing approval. Exondys 51 recorded spectacular gross sales progress up to now few quarters regardless of the COVID-19 pandemic. Vyondys 53 and Amondys 45 have additionally seen robust demand since their launch. Per administration, these three medicine have the potential to deal with almost a 3rd of all sufferers with DMD in the US.
SRPT’s Zacks Rank
Sarepta at the moment carries a Zacks Rank #3 (Maintain).
Sarepta Therapeutics, Inc. Value
Sarepta Therapeutics, Inc. price | Sarepta Therapeutics, Inc. Quote
Key Picks Amongst Biotech Shares
Some better-ranked shares from the sector are ANI Prescribed drugs ANIP and CytomX Therapeutics CTMX, every sporting a Zacks Rank #1 (Sturdy Purchase) at current. You’ll be able to see the complete list of today’s Zacks #1 Rank stocks here.
Up to now 60 days, estimates for ANI Prescribed drugs’ 2025 earnings per share (EPS) have risen from $5.54 to $6.35. EPS estimates for 2026 have elevated from $6.75 to $7.21 throughout the identical interval. 12 months so far, shares of ANIP have risen 16%.
ANIP’s earnings beat estimates in every of the trailing 4 quarters, delivering a mean shock of 17.32%.
Up to now 60 days, estimates for CytomX Therapeutics’ 2025 EPS have improved from a lack of 31 cents to earnings of 25 cents. Throughout the identical timeframe, estimates for loss per share for 2026 have narrowed from 65 cents to 31 cents. 12 months so far, shares of CytomX have misplaced 41%.
CTMX’s earnings beat estimates in three of the trailing 4 quarters and missed the mark as soon as, delivering a mean shock of 180.70%.
7 Greatest Shares for the Subsequent 30 Days
Simply launched: Specialists distill 7 elite shares from the present record of 220 Zacks Rank #1 Sturdy Buys. They deem these tickers “Most Probably for Early Value Pops.”
Since 1988, the complete record has overwhelmed the market greater than 2X over with a mean achieve of +24.3% per 12 months. So make sure to give these hand picked 7 your instant consideration.
Roche Holding AG (RHHBY) : Free Stock Analysis Report
Sarepta Therapeutics, Inc. (SRPT) : Free Stock Analysis Report
ANI Pharmaceuticals, Inc. (ANIP) : Free Stock Analysis Report
CytomX Therapeutics, Inc. (CTMX) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
The views and opinions expressed herein are the views and opinions of the creator and don’t essentially mirror these of Nasdaq, Inc.
